Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to p ...

B. Riley decreased their FY2027 earnings estimates for shares of Geron in a research note issued to investors on Tuesday, ...

B. Riley dropped their FY2025 earnings per share (EPS) estimates for shares of Geron in a research report issued to clients ...

Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section on Artivabio.com. A webcast replay will be made available following the ...

In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...

Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.

The live call may be accessed by dialing (800) 579-2543 for domestic callers and (785) 424-1789 for international callers and entering the conference ID: KURAQ4. A live webcast and archived replay of ...

Kimberly Stegmaier, MD, was named Chair of Pediatric Oncology at Dana-Farber Cancer Institute and Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital, in an ...

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.